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Abstract
Background: We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer
susceptibility genes in BRCA1/2 mutation-negative Korean patients with a high risk for hereditary breast cancer
using a comprehensive multigene panel that included 35 cancer susceptibility genes.
Methods: Samples from 120 patients who were negative for BRCA1/2 mutations, but had been diagnosed with
breast cancer that was likely hereditary, were prospectively evaluated for the prevalence of high-penetrance and
moderate-penetrance germline mutations.
Results: Nine patients (7.5%) had at least one pathogenic or likely pathogenic variant. Ten variants were identified
in these patients: TP53 in two patients, PALB2 in three patients, BARD1 in two patients, BRIP1 in two patients, and
MRE11A in one patient. We also identified 30 types of 139 variants of unknown significance (VUS). High-penetrance
germline mutations, including TP53 and PALB2, tended to occur with high frequency in young (< 35 years) breast
cancer patients (4/19, 21.1%) than in those diagnosed with breast cancer at ≥35 years of age (1/101, 1.0%; p = 0.003).
Conclusions: These combined results demonstrate that multigene panels offer an alternative strategy for identifying
veiled pathogenic and likely pathogenic mutations in breast cancer susceptibility genes.
Keywords: Breast neoplasms, Neoplastic Syndromes, Hereditary, Beyond BRCA1/2, Multigene panel, Next generation
sequencing
Background
The identification of BRCA1 and BRCA2 germline muta-
tions as predictors of cancer susceptibility significantly
improved the diagnosis and prevention of hereditary
breast and ovarian cancers (HBOC). Recent advances in
genetic testing have enabled the discovery of novel genes
that increase the risk of cancer in patients with familial
predisposition. Multiple research laboratories have eval-
uated these cancer-associated mutations in patients who
are negative for BRCA1/2 mutations, but still have a
high risk of HBOC. These efforts have identified muta-
tions in moderate-risk genes, such as ATM, BRIP1,
CHEK2, BARD1, MRE11A, NBN, RAD50, RAD51, and
XRCC2, as well as those in high-penetrance genes, in-
cluding TP53, PTEN, STK11, CDH1, and PALB2, have
been reported across diverse ethnic populations [1].
Next generation sequencing (NGS) can provide de-
tailed genetic information via multi-gene panel assays
[2]. However, the application of NGS multigene panel
test in a clinical setting represents a considerable
challenge. It is necessary to not only validate this novel
technique, but also to select candidate susceptibility
genes. Furthermore, mutations indicative of cancer sus-
ceptibility vary across ethnicities; therefore, it is import-
ant to understand the clinical and genetic characteristics
of multiple susceptibility genes identified by NGS multi-
gene panels in each ethnic population.
In this study, we used comprehensive multigene panels
that included 35 known or suspected cancer susceptibility
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genes to examine BRCA1/2 mutation-negative Korean
patients who had clinical features indicative of hereditary
breast cancer. We also investigated the feasibility of multi-
gene panel testing for Korean patients, and evaluated po-
tential clinicopathological risk factors related to germline
mutations other than BRCA1/2.
Methods
Study population
The study population included 182 Korean BRCA1/2
mutation-negative breast cancer patients with a familial
predisposition who were referred to the Cancer Preven-
tion Center, Yonsei Cancer Center, Seoul, Korea between
March 1, 2015 and November 11, 2016. Sixty-two
patients opted to not participate. Finally, a total of 120
patients were enrolled in the study. Suspected clinical
features of hereditary breast cancer were defined as fol-
lows: (1) at least one case of breast or ovarian cancer in
first- or second-degree relatives; (2) a first diagnosis of
breast cancer before age 40; (3) bilateral breast cancer;
and (4) co-diagnosis of breast and ovarian cancers in the
same patient.
Panel-based mutation analysis
Germline DNA was extracted from the participants’ per-
ipheral blood samples. We used a customized targeted
capture sequencing panel (OncoRisk®, Celemics, Seoul,
Korea) which included all coding sequences and intron-
exon boundaries of the coding exon from 35 cancer pre-
disposition genes (BRCA1, BRCA2, PALB2, BARD1,
BRIP1, RAD51C, RAD51D, RAD50, NBN, MRE11A, ATM,
CHEK2, TP53, PTEN, APC, BLM, BMPR1A, CDH1,
CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6,
MUTYH, PMS2, POLE, PRSS1, RET, SLX4, SMAD4,
STK11, VLH, and WT1). Products with each capture reac-
tion were sequenced by 100 base pair paired-end reads on
a MiSeq platform (Illumina, San Diego, CA). High-quality
sequencing data with an average depth of 500−1000 folds
were obtained.
We identified all single base pair substitutions,
insertion-deletions, and copy number variants (CNVs) in
each gene. Split-read-based detection of large insertions
and deletions was conducted using the Pindel and
Manta algorithms. CNVs detected by ExomeDepth soft-
ware [3] were further crosschecked with our custom
pipelines, which retrieved base-level depth of coverage
for each binary alignment map (BAM) file using
SAMtools software (http://samtools.sourceforge.net) and
normalized the depths in the same batch (Additional file 1:
Figure S1). All likely deleterious mutations were
validated by Sanger sequencing, and all possible large
rearrangements were confirmed by the multiplex
ligation-dependent probe amplification (MLPA) method
(Additional file 1: Figure S2).
Genetic variants were classified using a five-tier system
following guidelines from the American College of
Medical Genetics and Genomics (ACMG) as follows: patho-
genic, likely pathogenic, variants of unknown significance
(VUS), likely benign, or benign/polymorphism [4]. We used
the Sorting Intolerant From Tolerant (SIFT, http://sift.
bii.a-star.edu.sg/) and Polymorphism Phenotyping-2
(PolyPhen-2, http://genetics.bwh.harvard.edu/pph2) to
generate in silico predictions of several of the identified
nonsynonymous variants. Using large rearrangements of
exons, pathogenic and likely pathogenic variants were
considered as mutations, for consistency with previous
studies [5].
Results
Baseline characteristics of the patients are presented in
Additional file 2: Table S1. A total of 7.5% (9/120) of
patients were found to carry at least one pathogenic or
likely pathogenic variant. A total of ten gene variants
(Fig. 1a) were identified in nine patients: TP53 in two
patients, PALB2 in three patients, BARD1 in two patients,
BRIP1 in two patients, and MRE11A in one patient. We
detected a large deletion from exon 2−9 in the TP53
gene, and the other pathogenic variants identified were as
follows: PALB2 (c.3267_3268delGT, p.Phe1090SerfsTer6,
rs587781890; c.2257C > T, p.Arg753Ter, rs180177110;
and c.695delC, p.Gly232ValfsTer6); BARD1 (c.1345C > T,
p.Gln449Ter); BRIP1 (c.1066C > T, p.Arg356Ter,
rs730881633; and exon 5–6 deletion); and MRE11A
(c.1773_1774delAA, p.Gly593LysfsTer4). Likely pathogenic
variants were found in TP53 (c.733G >A, p.Gly245Ser,
rs28934575). Pathogenic variants in PALB2 and MRE11A
were identified in a 34-year-old patient who was co-
diagnosed with breast and gastric cancer (Table 1). Three
of the pathogenic variants identified in this study were not
reported previously.
A total of 87 patients (72.5%) had at least one VUS (me-
dian, 1; range, 0–3). A total of 139 VUS were identified in
30 cancer susceptibility genes, including SLX4 (n = 11),
BLM (n = 10), POLE (n = 10), ATM (n = 9), CDH1 (n = 9),
CHEK2 (n = 9), BRCA2 (n = 8), RAD50 (n = 7), BRIP1
(n = 6), EPCAM (n = 5), PALB2 (n = 5), PRSS1 (n = 5),
TP53 (n = 5), APC (n = 4), MLH1 (n = 4), RET (n = 4),
MRE11A (n = 3), MSH2 (n = 3), MSH6 (n = 3), MUTYH
(n = 3), RAD51D (n = 3), STK11 (n = 3), BMPR1A (n = 2),
BRCA1 (n = 2), CDKN2A (n = 1), MEN1 (n = 1), NBN
(n = 1), PMS2 (n = 1),VHL (n = 1), andWT1 (n = 1) (Fig. 1b).
First diagnosis of breast cancer at a relatively young
age (<35 years) was correlated with pathogenic or likely-
pathogenic variants in high-penetrance cancer suscepti-
bility genes. Pathogenic variants in high-penetrance
genes were detected in 21.1% (4/19) of these patients,
which was significantly higher than that for patients who
Park et al. BMC Cancer  (2018) 18:83 Page 2 of 8
were first diagnosed with breast cancer at age ≥ 35 years
(1/101, 1.0%, p = 0.003) (Table 2).
Discussion
Previous studies using multigene panel tests identified
cancer susceptibility genes in 2.1−16.8% of BRCA1/2
mutation-negative patients [5–11]. Our tests of high-
penetrance genes identified a large exon deletion in TP53,
and pathogenic and likely pathogenic variants in TP53
and PALB2 (Table 1). We also identified a frameshift mu-
tation ofMRE11A c.1773_1774delAA (p.Gly593LysfsTer4)
in a patient with a PALB2 mutation. The MRE11 protein
functions in non-homologous end-joining and homolo-
gous recombination, which occur during the repair of
double-stranded DNA breaks [12]. Therefore, the risk for
patients with concurrent dysfunction in PALB2 and
MRE11A is unclear and should be assessed in future
studies. Because the two frameshift variants in PALB2
(c.3267_3268delGT, p.Phe1090SerfsTer6, rs587781890;
and c.695delG, p.Gly232ValfsTer6) were not found in
the control group, the variants met the criteria to be
likely pathogenic according to the ACMG guideline
(PVS1 and PM2) (Table 1) [4]. One nonsense variant in
PALB2 (c.2257C > T p.Arg753Ter, rs180177110) had a
higher prevalence in affected patients compared to the
control group [odds ratio (OR), 127.0; 95% confidence
interval (CI), 14.1–1140.1; p < 0.0001]. Therefore, this
variant conformed to the criteria to be classified as
pathogenic according to ACMG guidelines (PVS1 and
PS4) (Table 1) [4]. In addition, a missense variant in
TP53, c.733G > A (p.Gly245Ser, rs28934575) was classi-
fied as a pathogenic or likely pathogenic variant in the
ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/),
and met the criteria for a likely pathogenic variant
according to the ACMG guidelines (PM2, PM5, PP2, PP3,
and PP5) (Additional file 2: Table S2) [4].
Pathogenic or likely pathogenic variants also were
detected in BRCA1-associated RING domain 1 (BARD1)
and BRCA1-interacting protein C-terminal helicase 1
(BRIP1). BARD1 and BRIP1 encode proteins that interact
with the BRCA1 protein during the repair of DNA double-
stranded break, and pathogenic variants of these genes
have been investigated [13]. However, there is a contro-
versy as to whether these rare variants are clinically associ-
ated with a risk of breast cancer [11, 14]. In a previous
study that screened for BRIP1 mutations among 235
Korean patients with BRCA1/2 mutation-negative high-risk
breast cancers using fluorescent-conformation sensitive gel
electrophoresis (F-CSGE), there was no case of a protein-
truncating BRIP1 mutation, which suggests that the preva-
lence of BRIP1 mutations is likely to be low in the Korean
population [15].
Cell cycle checkpoint kinase 2 (CHEK2) is a well-
established moderate-penetrance breast cancer gene. Sev-
eral studies have shown that essentially no case of CHEK2
(c.1100delC) was observed in Asian populations, in con-
trast to the observed prevalence in European populations
[16–19]. Liu and colleagues reported that the CHEK2
c.1111C > T (p.His371Tyr, rs531398630) variant was ob-
served in 4.24% (5/118) of Chinese familial breast cancer
cases without BRCA1/2 mutations, and was associated
with dysfunctional phosphorylation of T68 in the SQ/TQ
rich domain, which is an activation point following DNA
damage [18]. We also identified CHEK2 c.1111C > T
variants in 2.5% (3/120) of Korean breast cancer patients
without BRCA1/2 mutations (Additional file 2: Table S2).
Population-based investigations are required to establish
the prevalence of this variant, especially in Asian patients.
We identified the CHEK2 c.908 + 2delT variant in one
a b
Fig. 1 a Percentage of patients with pathogenic or likely pathogenic mutations corresponding with each gene. b Number of patients with
variants of uncertain significance (VUS) for each gene (n = 120 patients total)
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patient, and it was classified as likely pathogenic according
to the ACMG guideline (Additional file 2: Table S2).
However, we did not classify this variant as a positive
result because the experimental study was not sufficient.
In the current study, clinically important likely patho-
genic or pathogenic variants of high-penetrance genes
were identified in only five (4.2%) patients (TP53 in two
patients, and PALB2 in three patients). These variants
were identified in 4 of 19 patients (21.1%) with early-
onset breast cancer (< 35 years old at onset) (Table 2). A
previous study identified cancer susceptibility mutations
in 11% of BRCA1/2-negative patients with early-onset
breast cancer (diagnosed at <40 years of age) [20].
Considering the frequency of pathogenic variants of
high-penetrance genes in patients with early-onset
cancer, clinicians should be encouraged to consider
performing multigene panel tests for these patients if
their conventional BRCA1/2 tests are negative.
This study has several limitations. The primary limita-
tion is the small number of patients (n = 120), which
provides only limited data for cancer susceptibility genes
in Korean patients with breast cancer. A large-scale co-
hort study will be required to establish the accurate
prevalence and spectrum of pathogenic variants in these
patients. The majority of patients (87 of the 120, 72.5%)
had VUS. A functional and population-based study will
be necessary to clarify the clinical meaning of these
VUS. Despite these limitations, to the best of our know-
ledge, this is the first prospective study to apply
customized multigene panels to BRCA1/2 mutation-
negative Korean patients with a high risk for HBOC. A
recent study conducted by Couch et al. assessed the
commercial multigene panel test results of 65,057 pa-
tients with breast cancer; however, the frequency, pheno-
typic association, and cancer risks related to each variant
were analyzed among Caucasian women only [11]. Re-
garding diversity of prevalence of the genetic variants,
more prospective studies will be required among diverse
ethnic populations.
Conclusions
Wider application of multigene panel tests that include
high-penetrance cancer susceptibility genes, so-called “be-
yond BRCA1/2 genes”, will likely provide clinically relevant
information for some patients with high risk for hereditary
cancer [1, 13, 21]. However, these panels can produce
abundant and conflicting results in clinical practice. To ef-
ficiently utilize these data, clinical databases should be
established with respect to ethnic backgrounds, and genetic
results should be carefully applied for high-risk patients.
Additional files
Additional file 1: Figures S1 and S2. This file includes the methods
detecting pathogenic variants and lage deletion in this study; depth
of coverage and method for detection of large insertion-deletion of
exon using next-generation sequencing, and confirmation of
Table 2 Association between the clinicopathological features of suspected hereditary breast cancer and the pathogenic or likely
pathogenic variants of non-BRCA cancer predisposition genes (n = 120 patients)
Clinicopathological features High-penetrance
mutations
Moderate-penetrance
mutations
None or VUS
Number ofpatients % Number ofpatients % Number ofpatients % p-value
Breast cancer site
Bilateral 2 18.2 0 0 9 81.8 0.106*
Unilateral 3 2.8 4 3.7 102 93.5
Breast cancer subtype (n = 117, excluding patients with unknown breast cancer subtypes)
TNBC 0 0 1 4.5 21 95.5 >0.99*
hormone + and/or HER2+ 4 4.2 3 3.2 88 92.6
Concomitant diagnosis with ovarian cancer
Yes 0 0 0 0 3 100 >0.99*
No 5 4.3 4 3.4 108 92.3
Age at first diagnosis of breast cancer
< 35 years 4 21.1 0 0 15 78.9 0.003*
≥ 35 years 1 1.0 4 4.0 96 95.0
Family history of young (< 50 years old at diagnosis) breast and/or ovarian cancer patients within 2nd degree family
Yes 2 6.3 3 9.4 27 84.3 0.053*
No 3 3.4 1 1.1 84 95.5
Abbreviations: HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; VUS, variant of unknown significance. *Analyzed using
Fisher’s exact test
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deleterious mutations using Sanger sequencing or MLPA in four pa-
tients. (PDF 1477 kb)
Additional file 2: Tables S1 and S2. This file includes two tables
regarding baseline characteristics of study participants, possibly
pathogenic variants and the classification according to ACMG guidelines
mentied in the main manuscript. (DOCX 24 kb)
Abbreviations
ACMG: American College of Medical Genetics and Genomics; AJCC: American Joint
Committee on Cancer; BAM: Binary alignment map; BARD1: BRCA1-associated RING
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